[Clinical study and trial of penetration to the cerebrospinal fluid of aspoxicillin in the pediatric field].
Penetration of aspoxicillin (ASPC), a new semisynthetic penicillin, to cerebrospinal fluid (CSF) and clinical studies against bacterial infections were carried out and the following results were obtained. The concentration of ASPC in CSF was below 1 microgram/ml at 1 hour after intravenous administration of about 50 mg/kg dose to 2 cases of aseptic meningitis on the acute stage. The concentration of ASPC in CSF was above 10 micrograms/ml at 1 hour after intravenous administration of about 80 mg/kg dose to 3 cases of purulent meningitis on the acute stage, and was above 2 micrograms/ml even on the recovering stage. On each stage, its concentration was more than minimum inhibitory concentration of H. influenzae (less than or equal to 0.05 microgram/ml; at inoculum size of 10(6) cells/ml). Clinical efficacy of ASPC was good in all 3 cases of purulent meningitis, excellent in 3 cases, good in 3 cases and poor in 1 case out of 7 cases of septicemia, good in 2 cases and poor in 1 case out of 3 cases of gastroenteritis, respectively. And clinical efficacy of other diseases were excellent or good, that were 2 cases of tonsillitis, 2 cases of soft tissue abscess, 1 case of purulent lymphadenitis and 1 case of urinary tract infection, respectively. Side effects were mild eosinophilia in only 2 cases out of 22 cases.
D000658:Amoxicillin / Q000031:analogs & derivatives* / Q000134:cerebrospinal fluid / Q000494:pharmacology / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D007223:Infant; D007275:Injections, Intravenous; D008297:Male; D008581:Meningitis / Q000188:drug therapy; D018805:Sepsis / Q000188:drug therapy
C037485:aspoxicillin; D000658:Amoxicillin